A Phase II trial of edatrexate in patients with advanced renal cell carcinoma: An Eastern Cooperative Oncology Group Study

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 20, Issue 3, 1997, Pages 251-253

  Dreicer, Robert ^a,g   Propert, Kathleen J ^b   Kuzel, Timothy ^c   Kirkwood, John M ^d   O'Dwyer, Peter J ^e   Loehrer, Patrick J ^f  

^a UNIVERSITY OF IOWA   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e FOX CHASE CANCER CENTER   (United States)

^f INDIANA UNIVERSITY   (United States)

^g UNIVERSITY OF IOWA   (United States)

Author keywords

Edatrexate; Renal cell carcinoma

Indexed keywords

EDATREXATE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CRYOTHERAPY; DOSE RESPONSE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; MALE; METASTASIS; PHASE 2 CLINICAL TRIAL; PROGNOSIS; STOMATITIS;

ADULT; AGED; AMINOPTERIN; ANTINEOPLASTIC AGENTS; BONE MARROW DISEASES; CARCINOMA, RENAL CELL; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REMISSION INDUCTION; STOMATITIS; SURVIVAL ANALYSIS;

EID: 0030917278     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199706000-00008     Document Type: Article

References (10)

1. Grant SC, Kris MG, Young CW, Sirotnak FM. Edatrexate, an antifolate with antitumor activity: a review. Cancer Invest 1993; 11:36-45.
2. Gralla RJ. Edatrexate studies in non-small cell lung cancer. Lung Cancer 1995; 12(suppl):187-91.
3. Schorngale JH, Verweij J, de Mulder PH, et al. Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study. J Clin Oncol 1995;13:1649-55.
4. Elson PJ, Witte RS, Trump DL. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 1988;48:7310-3.
5. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
6. Hrushesky WJ, Murphy GP. Currents status of the therapy of advanced renal carcinoma. J Surg Oncol 1977;9:277-88.
7. Fosså SD, Droz JP, Pavone-Macaluso MM, et al. Vinblastine in metastatic renal cell carcinoma: EORTC Phase II trial 30882. Eur J Cancer 1992;28A:878-80.
8. Thiebaut F, Tsuruo T, Hamada H, et al. Immunohistochemical localization in normal tissues of different epitopes in multidrug transport protein p170: evidence for localization in brain capillaries and cross reactivity of one antibody with a muscle protein. J Histochem Cytochem 1989;37:159-64.
9. Motzer R, Lyn P, Fischer P, et al. Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. J Clin Oncol 1995; 13:1958-65.
10. Lee JS, Murphy WK, Shirinian MH, Pang A, Hong WK. Alleviation by leucovorin of the dose-limiting toxicity of edatrexate: potential for improved therapeutic efficacy. Cancer Chemother Pharmacol 1991;28:199-204.